List of Zokinvy drug patents

Zokinvy is owned by Eiger Biopharms.

Zokinvy contains Lonafarnib.

Zokinvy has a total of 2 drug patents out of which 0 drug patents have expired.

Zokinvy was authorised for market use on 20 November, 2020.

Zokinvy is available in capsule;oral dosage forms.

Zokinvy can be used as reducing the risk of mortality in hutchinson-gilford progeria syndrome (hgps).

Drug patent challenges can be filed against Zokinvy from November, 2024.

The generics of Zokinvy are possible to be released after 20 November, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8828356 EIGER BIOPHARMS Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
Oct, 2023

(8 months from now)

US7838531 EIGER BIOPHARMS Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
Jul, 2024

(1 year, 5 months from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 20, 2027
New Chemical Entity Exclusivity (NCE) Nov 20, 2025

Drugs and Companies using LONAFARNIB ingredient

NCE-1 date: November, 2024

Market Authorisation Date: 20 November, 2020

Treatment: Reducing the risk of mortality in hutchinson-gilford progeria syndrome (hgps)

Dosage: CAPSULE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in